Burkholderia Infections - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Burkholderia Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Burkholderia Infections - Pipeline Review, H1 2016', provides an overview of the Burkholderia Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkholderia Infections
- The report reviews pipeline therapeutics for Burkholderia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Burkholderia Infections therapeutics and enlists all their major and minor projects
- The report assesses Burkholderia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Burkholderia Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Burkholderia Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Burkholderia Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Burkholderia Infections Overview 8
Therapeutics Development 9
Pipeline Products for Burkholderia Infections - Overview 9
Pipeline Products for Burkholderia Infections - Comparative Analysis 10
Burkholderia Infections - Therapeutics under Development by Companies 11
Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes 12
Burkholderia Infections - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Burkholderia Infections - Products under Development by Companies 16
Burkholderia Infections - Products under Investigation by Universities/Institutes 17
Burkholderia Infections - Companies Involved in Therapeutics Development 18
Arno Therapeutics, Inc. 18
Bavarian Nordic A/S 19
Emergent BioSolutions Inc. 20
Eumedica SA 21
Grifols, S.A. 22
NanoBio Corporation 23
Sarepta Therapeutics, Inc. 24
Soligenix, Inc. 25
Syntiron LLC 26
TGV-Laboratories 27
Vault Pharma Inc. 28
Burkholderia Infections - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AR-13 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ARD-3100 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ARD-3150 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Burkholderia pseudomallei vaccine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Burkholderia vaccine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Burkholderia vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
dusquetide - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
EV-035 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
GC-072 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
melioidosis vaccine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Mul-1867 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
NB-401 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
SGX-101 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
SGX-943 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
temocillin - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
VPI-231 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Burkholderia Infections - Dormant Projects 68
Burkholderia Infections - Discontinued Products 69
Burkholderia Infections - Product Development Milestones 70
Featured News & Press Releases 70
May 31, 2016: FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis 70
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 70
Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072 71
Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 71
Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 71
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 72
Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 72
Oct 15, 2009: NanoBio's Nanoemulsion Kills Drug-Resistant Bacteria Found In Cystic Fibrosis Patients 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for Burkholderia Infections, H1 2016 9
Number of Products under Development for Burkholderia Infections - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Comparative Analysis by Unknown Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Burkholderia Infections - Pipeline by Arno Therapeutics, Inc., H1 2016 18
Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H1 2016 19
Burkholderia Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 20
Burkholderia Infections - Pipeline by Eumedica SA, H1 2016 21
Burkholderia Infections - Pipeline by Grifols, S.A., H1 2016 22
Burkholderia Infections - Pipeline by NanoBio Corporation, H1 2016 23
Burkholderia Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016 24
Burkholderia Infections - Pipeline by Soligenix, Inc., H1 2016 25
Burkholderia Infections - Pipeline by Syntiron LLC, H1 2016 26
Burkholderia Infections - Pipeline by TGV-Laboratories, H1 2016 27
Burkholderia Infections - Pipeline by Vault Pharma Inc., H1 2016 28
Assessment by Monotherapy Products, H1 2016 29
Number of Products by Stage and Target, H1 2016 31
Number of Products by Stage and Mechanism of Action, H1 2016 33
Number of Products by Stage and Route of Administration, H1 2016 35
Number of Products by Stage and Molecule Type, H1 2016 37
Burkholderia Infections - Dormant Projects, H1 2016 68
Burkholderia Infections - Discontinued Products, H1 2016 69